* = Presenting author

Poster presentations: Clinical Therapy and observation (2011)

P136. Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe ulcerative colitis

P137. Effect of concomitant immunomodulator use on the efficacy of adalimumab in Crohn's disease patients stratified by prior anti-TNF use

P138. Infliximab modulates IL23–IL17 axis in patients with inflammatory bowel diseases

P139. Different scoring methods affect the accuracy of clinical outcomes in ulcerative colitis. Post-hoc analysis in a phase 2a study with interferon-β-1a

P140. Anti-TNF therapy and pregnancy in inflammatory bowel disease: A prospective cohort study from the GETAID [GETAID]

P141. Cost effectiveness of standardised ferric carboxymaltose treatment versus individually calculated iron sucrose treatment for IBD-associated iron deficiency anaemia

P142. Sharp decrease in calprotectin as a biomarker for remission in UC patients under infliximab therapy

P143. Transplantation of allogeneic mesenchymal stromal cells of bone marrow reduces the level of antibodies to infliximab in patients with Crohn's disease

P144. Laboratory predictors of the effectiveness of transplantation of allogeneic mesenchymal stromal cells of bone marrow in patients with ulcerative colitis

P145. Is elevated CRP a predictor of efficacy in ulcerative colitis? Post-hoc analysis from a placebo-controlled study with interferon-β-1a

P146. Adherence to adalimumab therapy in Crohn's disease: A French multicenter experience

P147. Predictors of efficacy, mucosal healing and need for dose intensification at 12-months of adalimumab therapy in patients with Crohn's disease. National data from Hungary

P148. Disability in inflammatory bowel disease (IBD): Developing ICF core sets for patients with IBD based on the WHO international classification of functioning, disability and health

P149. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: A multicenter study [Grupo Joven GETECCU]

P150. Female fertility after pouch surgery

P151. Shorter time to cessation of rectal bleeding with combined oral and topical mesalazine (PENTASA^®) for ulcerative colitis: Results from the PINCE trial

P152. Influence of treatment with azathioprine on the risk of surgery in patients with Crohn's disease

P153. Tacrolimus treatment in ulcerative colitis – A three center experience

P154. Tolerability and safety of conventional thiopurines concomitantly with allopurinol in IBD-patients with a skewed thiopurine metabolism

P155. In-vitro dissolution testing of 5-aminosalicylic acid release from pH dependent mesalazine formulations

P156. Quality of life, anxiety and depression in patients with inflammatory bowel diseases depend of extraintestinal manifestations

P157. Improvement in hematological status and symptoms in IBD patients using ferric carboxymaltose (Ferinject^®): A German multicenter non-interventional study

P158. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn's disease

P159. Response to the 2009 vaccine for influenza A/H1N1 in patients with inflammatory bowel disease on anti TNFα therapy

P160. Ten years of infliximab for Crohn's disease: Outcome in 469 patients from two tertiary referral centers

P161. Immune response to influenza A/H1N1 2009 vaccine in patients with inflammatory bowel disease on anti TNF-α therapy in vivo and in vitro

P162. Infliximab in steroid-dependent ulcerative colitis

P163. Outcomes of treatment with infliximab for ulcerative colitis and predictors of sustained clinical response

P164. Safety of biological therapy during pregnancy in women with inflammatory bowel disease: Experience of a single centre

P165. Endoscopic treatment of dysplasia in ulcerative colitis – median term outcome

P166. Efficacy of intensification regimes of biologic therapy in patients with inflammatory bowel disease and secondary non-response: Experience of a single referral centre

P167. Crohn & Bone-study: RCT of risedronate in patients with Crohn's disease and osteopenia [on behalf of the Initiative on Crohn's and Colitis¹]

P168. The majority of patients with inflammatory bowel disease in clinical remission has mucosal inflammation

P169. Risk of permanent stoma in Crohn's colitis: A comparison study between pre-biological era and biological era

P170. Impaired intestional iron absorption in patients with inflammatory bowel disease correlates with disease activity

P171. MMX^® mesalazine 2.4 g/day for the maintenance of disease quiescence: Efficacy in patients with ulcerative colitis, regardless of prior treatment

P172. Mucosal TNF-alpha level as a criterion for when to stop treatment with adalimumab in patients with Crohn's disease? A preliminary report

P173. Ehealth: Optimization of infliximab treatment and disease course via self-initiated web-based solution in Crohn's disease

P174. Is there a difference between self-assessed patient-reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon-β-1a

P175. Thiopurine metabolism in inflammatory bowel diseases: A worldwide survey of experts

P176. Endoscopic treatment with self-expanding metal stents in Crohn's disease strictures

P177. Adalimumab for patients with Crohn's disease and secondary loss of response or severe allergy to infliximab

P178. An audit of adherence to anti-TNF therapy in patients with inflammatory bowel disease

P179. Long-term efficacy and safety of cyclosporine as a rescue therapy in acute, steroid-refractory severe ulcerative colitis: Switching to infliximab is more effective than treating with concomitant immunomodulators

P180. Laparoscopic emergency colectomy for ulcerative colitis is associated with fewer adhesions compared to open emergency colectomy

P181. Adalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis

P182. Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease

P183. Thalidomide in immunosuppressors and anti-TNF unresponsive Crohn's disease patients: Efficacy and side effects

P184. Effectiveness and tolerability of maintenance methotrexate therapy in Crohn's disease patients; Analysis of a referral hospital-based 10-years intercept cohort

P185. Safety and efficacy of anti-TNFs in a consecutive series of Crohn's disease patients: A single center cohort study

P186. Treatment of perianal disease in Crohn's disease: Efficacy and safety of a multidisciplinary approach in a tertiary referral centre

P187. Examining the time to clinical recurrence with long-term MMX^® mesalazine maintenance therapy in patients with quiescent ulcerative colitis

P188. Intravenously administered ferric carboxymaltose and iron sucrose significantly improve quality of life in patients with IBD-associated iron deficiency anaemia

P189. Long-term follow-up of patients with Crohn's disease ileo-colonic strictures: Comparison of endoscopic and surgical therapy

P190. Endoscopic balloon dilatation of anastomotic strictures in patients with Crohn's disease: Effect of immediate endoscopic success and biological therapy

P191. Activity of nitric oxide-synthases and lipoperoxidation processes at the background of acetic acid-induced colitis due to amaranth oil introduced with aminoguanadine or celecoxib

P192. The dynamics of B-lymphocytes before and after transplantation of allogeneic mesenchymal stromal cells of bone marrow in patients with ulcerative colitis

P193. Can duration and severity of chronic bowel disease influence patients' psychosocial functioning?

P194. Adherence to medical treatment in children with inflammatory bowel disease: A paired patient–parent study

P195. Role of white cell apheresis in refractory ulcerative colitis: UK experience

P196. Are the results of multicenter trials hampered by country variability? Comparison between two endpoints used in a study with interferon-β-1a in ulcerative colitis

P197. Application of the WHO Fracture Risk Assessment Tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis

P198. Assessing relationships between compliance and clinical recurrence in patients with quiescent ulcerative colitis receiving MMX^® mesalazine 2.4 g/day as maintenance therapy: The phase IV SIMPLE trial

P199. Symptom improvement in mild-to-moderate ulcerative colitis after 1 week's acute treatment with MMX^® mesalazine 2.4 g/day

P200. Significant benefit of ferric carboxymaltose in IBD-associated iron deficiency anaemia is independent of patient baseline characteristics

P201. Effect of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study

P202. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease

P203. A post-hoc analysis: Mucosal healing in patients with ulcerative colitis associates with a reduced colectomy risk, high incidence of corticosteroid-free state and corticosteroid-free symptomatic remission

P204. Anti-TNFα agents induce psoriasiform eruption in IBD patients: Frequency and outcome

P205. The relationship among 6-TGN level, therapeutic effect and myelotoxicity of azathioprine: A study in a cohort of Chinese IBD patients

P206. The influence of 5-ASA on thiopurines in Chinese IBD therapy

P207. Oral tacrolimus therapy is useful for patients with intractable ulcerative colitis: A result of post-marketing analysis

P208. Long-term colectomy rate in severe steroid-refractory ulcerative colitis treated with infliximab as rescue therapy

P209. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study

P210. Are combined medical and surgical treatments optimal therapy for complex perianal fistula in Crohn's disease?

P211. Role of perception direction in patients with inflammatory bowel diseases and irritable bowel syndrome

P212. Pharmacokinetics of iron isomaltoside 1000 in inflammatory bowel disease (IBD)

P213. Use of azathioprine during pregnancy and in the postoperative setting in Crohn's disease: A worldwide survey of experts

P214. Mucosal healing an essential efficacy measure in ulcerative colitis: Effect of country-enrollment site in a phase IIa study with interferon-β-1a

P215. Biologic therapy versus conventional therapies in a series of Crohn's disease patients: A pair-matched study

P216. Effectiveness of a dose “de-escalation” strategy with anti-TNF drugs in patients with Crohn's disease (CD)

P217. Local injection of infliximab in severe fistulating perianal Crohn's disease: Long-term follow-up

P218. Evaluation of the burden of the disease in patients with Crohn's disease and complex perianal fistula

P219. Solid organ transplantation and inflammatory bowel disease (IBD)

P220. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 19 cases

P221. Anxiety and psychological stress in acute severe ulcerative colitis: Prevalence and effect on outcome

P222. Efficacy of different therapeutic options for spontaneous intraabdominal abscesses in Crohn's disease

P223. Skin lesions in patients with inflammatory bowel disease treated with immunomodulators and/or anti-tumor necrosis factor

P224. Use of adalimumab in anti-TNF naive Crohn's disease patients: Clinical experience in a multicenter cohort

P225. Effects of TNF-α antagonists on lipid profile in patients with IBD

P226. Prevention of infusion reactions to infliximab in pediatric patients

P227. Evaluation of safety and effectiveness of adalimumab therapy in symptomatic ileal Crohn's disease strictures

P228. Awareness of adverse effects of azathioprine among patients with inflammatory bowel disease

P229. Kinetics of the Anti-HBs titers after vaccination against hepatitis B virus (HBV) in patients with inflammatory bowel disease (IBD)

P230. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease

P231. No association between vedolizumab exposure and serum JC virus levels

P232. Adalimumab in steroid-dependent Crohn's disease patients: Analysis of efficacy, prognostic factors for clinical benefit and safety

P233. Comparative study to evaluate the effectiveness of two different vaccination protocols against hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients

P234. The effect of allopurinol on thiopurine metabolite concentrations in patients with inflammatory bowel disease

P235. Clinical value of measuring trough levels and human anti-chimeric antibodies in patients with inflammatory bowel disease who lost response to infliximab therapy

P236. The requirements of adolescents with inflammatory bowel disease for successful transition: Differing perceptions from a survey of adult and paediatric gastroenterologists

P237. Feasibility and safety of granulocytapheresis in Crohn's disease: A prospective cohort study

P238. Granulocytapheresis on the treatment of ulcerative colitis: Results from four centres in Castile and Leon

P239. Mycophenolate mofetil in inflammatory bowel disease: The experience of a third level hospital

P240. Predicting response to thiopurines – A single centre experience

P241. Thiopurines in the treatment of inflammatory bowel diseases (IBD) – A single centre experience

P242. Cost analysis of screening according to ECCO Guidelines for prevention of opportunistic infections in infliximab-treated IBD patients

P243. Inflammatory bowel disease itself is a more important risk factor for impaired health-related quality of life than non-adherence to medical therapy

P244. Prospective open-label pilot study to evaluate the safety, tolerability and efficacy of a novel adsorptive type cytapheresis module in patients with moderately to severely active ulcerative colitis

P245. The use of complementary therapies in inflammatory bowel disease – Do we know what our patients are taking?

P246. Technical performance of a novel adsorptive type cytapheresis module in patients with moderately to severely active ulcerative colitis

P247. Iron status and treatment of iron deficiency with ferric carboxymaltose in IBD patients: A retrospective, single center analysis

P248. Perceptions of the risks of continuation and cessation of maintenance therapy among patients with inflammatory bowel disease

P249. A real life retrospective analysis of drug expenditure reveals no significant cost difference between infliximab and adalimumab in the treatment of adult Crohn's disease

P250. Outcome of benign strictures in ulcerative colitis

P251. Information resources and inflammatory bowel disease – Who is informing our patients?

P252. Dose escalation of adalimumab subcutaneous injections for Crohn's disease in the real life clinical setting

P253. Cumulative ionizing radiation to image the small bowel: Are we really exceeding the safety limits?

P254. Adalimumab treatment in Crohn's disease patients previously non-responders or intolerant both to infliximab and certolizumab pegol: A referral centre experience

P255. Long-term infliximab treatment in Crohn's disease – Efficacy and safety

P256. The introduction of a formal IBD service is cost effective in reducing inpatient healthcare utilisation

P257. Available medical therapies do not affect development of major complications and need for surgery in Crohn's disease: Long-term prospective study on a population of 193 consecutive patients

P258. Anti-TNF as risk factor for free perforations in Crohn's disease? A case control study

P259. Influenza A H1N1 vaccine is safe and effective in patients with inflammatory bowel disease treated with thiopurines and TNF-α blockers

P260. Pretty baby: Successful use of anti-TNF-α therapy for Crohn's disease in pregnancy

P261. Improved quality of life in response to combined oral and topical mesalazine (PENTASA^®) for ulcerative colitis: Results from the PINCE trial

P262. Patient weight predicts time to loss of response with adalimumab in Crohn's disease

P263. Long-term clinical experience with vedolizumab for the treatment of inflammatory bowel disease: A phase 2 open-label safety extension study

P264. 30-day response to steroids predicts long term natural history of ulcerative colitis

P265. Preoperative infliximab therapy and postoperative complications after proctocolectomy with ileum pouch anal anastomosis (IPAA)

P266. The effect of appendectomy on the clinical course of ulcerative colitis – A systematic review

P267. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab [Grupo Joven GETECCU]

P268. Thiopurine metabolite measurement and the management of inflammatory bowel disease in South Australia: The first 18 months

P269. Effectiveness of the available therapeutic options in the treatment of perianal fistulas in patients with Crohn's disease (CD)

P270. Program of vaccination of patients with inflammatory bowel disease

P271. Management of patients with ulcerative colitis after proctocolectomy: Pouchitis is a frequent complication, sometimes with the need for biological therapy

P272. Outcome of cyclosporine rescue therapy or surgery in patients with steroid-refractory ulcerative colitis: Both improve the quality of life despite of the frequent complications

P273. Short and long-term outcome of infliximab therapy is different in acute, steroid-refractory and chronic, steroid-dependent ulcerative colitis

P274. Response to intravenous steroid therapy in the first few days of hospitalization determines the subsequent risk of colectomy in newly diagnosed ulcerative colitis patients

P275. Non-organ specific autoantibodies (NOSA) on TNF-α antagonists: A study in 40 patients with inflammatory bowel disease (IBD)

P276. Efficacy and effectiveness of biological therapy in inflammatory bowel disease (IBD): Comparative study between clinical practice and pivotal studies

P277. Optimal C-reactive protein cutoff point for predicting hospitalization in patients with moderately active Crohn's disease

P278. MRI guided biologic therapy for Crohn's perianal fistulae: 3 year follow up data

P279. MR enterography to guide treatment in children with Crohn's disease in the small bowel

P280. Analysis of the risk factors determining postoperative disease recurrence in an Irish Crohn's disease cohort

P281. The natural history of acute severe colitis in childhood ulcerative colitis

P282. One year infliximab administration for the treatment of chronic refractory pouchitis

P283. Treatment quality of patients suffering from IBD could be improved and costs significantly lowered by establishing a network between gastroenterologists and a health insurance in the Rhein-Main Region, Germany

P284. Nutrition status clinical assessment in children with moderate to severe Crohn's disease treated with total enteral nutrition (TEN)

P285. Smoking pattern of our Crohn's patients: Our intervention and outcome

P286. Prevalence of anaemia in children with inflammatory bowel disease

P287. Short and long-term effectiveness of azathioprine and mercaptopurine in patients with inflammatory bowel disease (IBD)

P288. Ileocolic resection: A safe and durable option for limited Crohn's disease of the terminal ileum

P289. Evaluation of efficacy and safety of induction therapy with curcumin enema in ulcerative colitis patients with mild to moderate proctitis

P290. Biological predictors of depression in IBD: Preliminary results of the ISA study

P291. Factors associated with premature death in inflammatory bowel disease

P292. Comparison of ulcerative colitis surveillance strategies: An analysis of cost-effectiveness

P293. Risk of malignancies in a single center cohort of IBD-patients treated with immunosuppressives and anti-TNF-antibodies

P294. Does medical or surgical option influence quality of life in UC patients with a previous severe flare?

P295. Treatment of acute or relapsing massive intestinal bleeding in Crohn's disease with anti-TNFα therapy

P296. Evolution of the bone mineral density in patients with inflammatory bowel disease: A five year follow-up study

P297. Cutaneous Crohn's disease

P298. Effect of immunosuppressive and biologic therapy in patients with inflammatory bowel diseases and HBV or HCV infection – A multicentre retrospective study

P299. Mucinous adenocarcinoma in perianal Crohn's disease after biological therapy: A four cases report

P300. Quality of life in Crohn's disease patients with endoscopic recurrence after surgery: Influence of thiopurine treatment

P301. Infliximab trough levels and anti-infliximab antibodies in rheumatoid arthritis and in IBD patients – A comparison from a single center

P302. Barriers to transition care for adolescents and young adults with inflammatory bowel disease: Results of a postal survey of adult and paediatric gastroenterologists

P303. Certolizumab pegol in patients with inflammatory or fistulizing Crohn's disease: A long term update of compassionate use

P304. Normalization of health-related quality of life in inflammatory bowel disease patients in long remission with anti-TNFα treatment

P305. Therapy-related adverse events in Crohn's disease (CD) – A comparison between thiopurines, infliximab and combined therapy

P306. Apheresis efficacy in ulcerative colitis

P307. A survey of patient opinion regarding the tolerability of, adherence to and efficacy of colesevelam compared with cholestyramine in the treatment of diarrhoea following ileal resection in Crohn's disease

P308. Parent–adolescent agreement regarding emotional and behavioral symptoms among adolescents with inflammatory bowel disease and population-based controls

P309. Interest of apheresis (Adacolumn^®) in the treatment of ulcerative colitis

P310. Late onset inflammatory bowel disease – View from a regional hospital

P311. Clinical presentation and risk factors for surgery in Crohn's disease: Analysis of 173 patients in China

P312. Cognitive-behavioural therapy (CBT) to manage inflammatory bowel disease (IBD): Preliminary findings

P313. Adherence to treatment in Latvian patients with inflammatory bowel disease

P314. Efficacy and safety of T2 for the prevention of postoperative Crohn's disease

P315. Infliximab therapy for pediatric inflammatory bowel disease

P316. Stored body iron serum markers are modulated by anti-TNF therapy in inflammatory bowel disease patients